Veru (NASDAQ:VERU – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Monday, Wall Street Zen reports.
Several other research analysts have also recently issued reports on the company. Weiss Ratings raised Veru from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, November 10th. Westpark Capital began coverage on Veru in a report on Tuesday, October 6th. They set a “buy” rating on the stock. Finally, Oppenheimer restated an “outperform” rating on shares of Veru in a research note on Wednesday, October 14th. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $24.50.
Read Our Latest Stock Report on VERU
Veru Price Performance
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. Royal Bank of Canada grew its holdings in Veru by 69.3% during the first quarter. Royal Bank of Canada now owns 12,239 shares of the company’s stock worth $27,000 after acquiring an additional 5,008 shares during the period. Renaissance Technologies LLC bought a new stake in Veru in the first quarter worth about $153,000. Finally, FNY Investment Advisers LLC bought a new stake in Veru in the second quarter worth about $328,000. Institutional investors own 47.16% of the company’s stock.
Veru Company Profile
Veru Inc. is a biopharmaceutical company focused on developing medicines for metabolic diseases and cancer. Its research programs include enobosarm, which is being studied to help preserve muscle during weight loss associated with GLP-1 medicines, as well as candidates investigated for breast and prostate cancer. The company has also developed sabizabulin, an investigational drug studied for cancer treatment. These medicines remain development-stage products; Veru’s clinical programs and priorities may change as research progresses.
Read More
- Five stocks we like better than Veru
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.
